CatalystFDA/Bio

XERIS BIOPHARMA HOLDINGS, INC. (XERS) DISCUSSES XP-8121 PROGRAM OVERVIEW, PHASE 3 STUDY DETAILS AND COMMERCIAL STRATEGY TRANSCRIPT - SEEKINGALPHA

Phase 3 study details and commercial strategy reveal pivotal trial catalysts.

What changed

Phase 3 study details and commercial strategy reveal pivotal trial catalysts.

Why it matters

Phase 3 study details and commercial strategy reveal pivotal trial catalysts. — impact context not separately stored; see What changed.

Sources